Evidence map›Paper›PMID 29775471›Full record

ArticlePloS one2018

Host-directed combinatorial RNAi improves inhibition of diverse strains of influenza A virus in human respiratory epithelial cells.

Michael A Estrin, Islam T M Hussein, Wendy B Puryear, Anne C Kuan, Stephen C Artim, Jonathan A Runstadler

Abstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. A determination of pan-pathogen antimicrobials?Medicine in drug discovery · 2022
    Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Michael A EstrinDivision of Comparative Medicine, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America.
Islam T M HusseinDivision of Comparative Medicine, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America.
Wendy B PuryearDivision of Comparative Medicine, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America.
Anne C KuanDivision of Comparative Medicine, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America.
Stephen C ArtimDivision of Comparative Medicine, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America.ORCID 0000-0003-4503-9024
Jonathan A RunstadlerDivision of Comparative Medicine, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America.ORCID 0000-0002-6747-7765

Funding

Biomedical Research Training for Veterinary ScientistsT32OD010978 · OD · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI FOX, JAMES G · 2012 to 2017
$2.2M
NIH HHS T32 OD010978
6 · The paper itself

Abstract

Influenza A virus infections are important causes of morbidity and mortality worldwide, and currently available prevention and treatment methods are suboptimal. In recent years, genome-wide investigations have revealed numerous host factors that are required for influenza to successfully complete its life cycle. However, only a select, small number of influenza strains were evaluated using this platform, and there was considerable variation in the genes identified across different investigations. In an effort to develop a universally efficacious therapeutic strategy with limited potential for the emergence of resistance, this study was performed to investigate the effect of combinatorial RNA interference (RNAi) on inhibiting the replication of diverse influenza A virus subtypes and strains. Candidate genes were selected for targeting based on the results of multiple previous independent genome-wide studies. The effect of single and combinatorial RNAi on the replication of 12 diverse influenza A viruses, including three strains isolated from birds and one strain isolated from seals, was then evaluated in primary normal human bronchial epithelial cells. After excluding overly toxic siRNA, two siRNA combinations were identified that reduced mean viral replication by greater than 79 percent in all mammalian strains, and greater than 68 percent in all avian strains. Host-directed combinatorial RNAi effectively prevents growth of a broad range of influenza virus strains in vitro, and is a potential therapeutic candidate for further development and future in vivo studies.

Indexed as

Influenza A virusRNAi TherapeuticsAnimalsBirdsBronchiCell Line, TumorDogsEpithelial CellsHEK293 CellsHumansInfluenza, HumanMadin Darby Canine Kidney CellsRNA InterferenceVirus Replication

Identifiers

PMID29775471
PMCPMC5959063

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.